Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (BMY) yesterday and set a price target of $59. The company’s shares closed yesterday at $49.60.
According to TipRanks.com, Divan has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.5% and a 41.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Merck & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $59.33 average price target, a 19.6% upside from current levels. In a report issued on January 4, Edward Jones also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
Based on Bristol Myers’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.69 billion and net profit of $1.9 billion. In comparison, last year the company earned revenue of $5.45 billion and had a GAAP net loss of $2.33 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
